Clinical trials: Neoplasm, Brain
Metastatic Rectal Adenocarcinoma, Brain Metastases
BRIANSTORM - Early Identification of Patients With Brain Metastases
A single arm observational study investigating the incidence of brain metastasis in patients with cancer recti and lung metastasis
- Trial name
- NCT05185557
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Aarhus University Hospital
Diffuse Intrinsic Pontine Glioma
A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas
Diffuse pontine gliomas are tumors on the pons portion of the brainstem. Their peak incidence is in children between 5 and 10 years old. Their location makes surgical resection impossible.
- Trial name
- NCT00036569
- Testing
- adjuvant therapy, pegylated interferon alfa
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Parkinson Disease, Neuroendocrine Tumors
124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.
The Feasibility of Novel 124I-MIBG Tracer in Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine tumors. Comparison with 123I-MIBG.
- Trial name
- NCT01931488
- Testing
- MIBG label with I123 or I124, SPECT imaging
- Where
- Israel
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Astrocytoma, Grades II, III and IV, Glioblastoma Multiforme
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Background: The brain is separated from the rest of the blood stream by the blood-brain barrier. This is like a filter that protects the brain. But is also a challenge when medicines need to get into the brain.
- Conditions
- Astrocytoma, Grades II, III and IV, Glioblastoma Multiforme, Giant Cell Glioblastoma, Glioma
- Trial name
- NCT03027388
- Testing
- LB-100
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma
Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma
This phase I/II trial studies the side effects and best dose of vorinostat and to see how well it works when given together with radiation therapy followed by maintenance therapy with vorinostat in treating younger patients with…
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma, Gliosarcoma
- Trial name
- NCT01189266
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 180 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Glioblastoma, Adult
Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
Monocentric randomized phase I/II trial, including 24 patients diagnosed with relapsing glioblastoma (GBM) irrespective of MGMT and IDH gene status.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, Adult, Glioma of Brain, Glioblastoma Multiforme of Brain
- Trial name
- IMA950-106 (NCT03665545)
- Testing
- IMA950/Poly-ICLC, IMA950/Poly-ICLC and pembrolizumab
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- University Hospital, Geneva
Cognitive/Functional Effects, Metastatic Cancer
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. PURPOSE: This phase II trial is studying how well avoiding the hippocampus during whole-brain radiation therapy works in treating patients with brain…
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT01227954
- Testing
- intensity-modulated radiation therapy
- Where
- 63 sites in United States, Canada
- Volunteers
- 113 people
- Sponsor
- Radiation Therapy Oncology Group
Brain Tumor, Primary
The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
An open-label, multicenter phase II clinical study to evaluate safety, efficacy and PK of HLX208 for refractory primary brain tumors with BRAF mutation
- Trial name
- NCT05092802
- Testing
- HLX208
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Henlius Biotech
Mild Cognitive Impairment, Cognitive Decline
Brain Health Together: A Live-Streaming Group-Based Digital Program
The purpose of this study is to develop and test a comprehensive Brain Health Together program for older adults living with cognitive decline.
- Conditions
- Mild Cognitive Impairment, Cognitive Decline, Cognitive Deterioration, Cognitive Deficits, Mild
- Trial name
- NCT05818423
- Testing
- Brain Health Academy, Brain Health Together, Maintain Brain Health Together
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- University of California, San Francisco
Brain Tumor
Biological Collection of Brain Tumors
The objective of this study is to build a collection of biological samples from patients with brain tumors.
- Trial name
- GLIOLI (NCT05571579)
- Testing
- blood and/or csf collection
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Hospices Civils de Lyon
Pilomyxoid Astrocytoma, Pilocytic Astrocytoma
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
This is a study to determine the safety and efficacy of the drug, mebendazole, when used in combination with standard chemotherapy drugs for the treatment of pediatric brain tumors.
- Conditions
- Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Glioma, Astrocytic, Optic Nerve Glioma
- Trial name
- NCT01837862
- Testing
- Mebendazole, Vincristine, Carboplatin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Julie Krystal
Vestibular Schwannoma
Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
A recent study by Plotkin et al. showed that bevacizumab (Avastin) treatment was followed by clinically meaningful hearing improvement, tumor-volume reduction, or both in some, but not all, patients with Vestibular Schwannoma…
- Trial name
- NCT01083966
- Testing
- Bevacizumab (Avastin)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Brain and Central Nervous System Tumors
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
RATIONALE: Radioactive drugs such as phosphorus 32 may be able to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of phosphorus 32 in treating patients with glioblastoma multiforme.
- Trial name
- NCT00004129
- Testing
- brachytherapy, phosphorus P32
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Center for Molecular Medicine
EGF-R Positive Non-Small Cell Lung Cancer, CNS Metastases
An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis
EGFR mutation positive advanced NSCLC patients with CNS metastases were associated with poor prognosis. Furmonertinib showed promising CNS efficacy in doses of 80 mg orally once daily or higher in patients with EGFR T790M…
- Trial name
- NCT06352502
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tang-Du Hospital
Brain Tumor, Brain Tumor, Recurrent
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).
- Conditions
- Brain Tumor, Brain Tumor, Recurrent, Brain Neoplasm, Brain Cancer
- Trial name
- NCT00747253
- Testing
- AutoLITT system
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Monteris Medical
Inherited Disease, Rare Diseases
Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.
General aim of the study is the improvement of the clinical knowledge of ultra-rare inherited metabolic and degenerative neurological diseases (prevalence less than 5:100,000) in adulthood through the systematic longitudinal…
- Conditions
- Inherited Disease, Rare Diseases, Metabolic Disease, Undiagnosed Disease
- Trial name
- NCT04880356
- Testing
- collection of data
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Glioblastoma, Small Cell Glioblastoma
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have tumors that express…
- Conditions
- Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
- Trial name
- ACT IV (NCT01480479)
- Testing
- Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH
- Where
- 223 sites in United States, Australia and 22 more
- Volunteers
- 745 people
- Sponsor
- Celldex Therapeutics
Brain Metastases, Adult, Cancer Brain
Hypofractionated Brain Radiationcavity
Stereotactic radiosurgery or hypofractionated radiotherapy of the resection cavity after metastasectomy in cancer patients with brain metastases
- Trial name
- NCT03561896
- Testing
- IGRT, SRS
- Where
- 6 sites in Switzerland
- Volunteers
- 56 people
- Sponsor
- Oncology Institute of Southern Switzerland
Multiple Myeloma
Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects
The purpose of this study is to see if MRI techniques can be used for early evaluation of cardiac amyloidosis which is sometimes seen in individuals with multiple myeloma.
- Trial name
- NCT01018927
- Testing
- Administering three additional MRI images
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Arkansas
Sellar and Suprasellar Masses, Pituitary Tumor
Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery
1. Access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy. 2.
- Trial name
- NCT04369703
- Where
- United States
- Volunteers
- 199 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.